Successful combined polychemotherapy and cytokine-genetic therapy in the treatment of cecal tumor (a case report)
Abstract
Background. Antitumor drug therapy plays a significant role in the treatment of metastatic colorectal cancer, increasing patient survival. The use of immuno-oncology agents in this treatment is limited, as most colorectal tumors are characterized by low immunogenicity. Cytokine gene therapy agents are gaining attention as agents capable of activating the antitumor immune response. Materials and methods. Patient T., 76, was followed up with a diagnosis of cT3N1M1 cecal cancer, multiple liver metastases, and peritoneal carcinomatosis. Histologically, adenocarcinoma, G3, was confirmed, with no signs of microsatellite instability, KRAS mut, NRAS wt, HER2/neu wt, and BRAF wt. A local oncology board decided to schedule courses of drug therapy according to the XELOX regimen. A contrast-enhanced computed tomography scan revealed a cecal neoplasm, regional lymphadenopathy, peritoneal carcinomatosis, and multiple liver lesions. Wishing to complete the prescribed treatment without developing significant toxicity, the patient voluntarily presented to the clinic to receive cyclophosphamide medications. Changes in Karnofsky performance status were monitored throughout the patient's treatment. Levels of tumor necrosis factor-alpha, carcinoembryonic antigen, and cancer antigen 19-9 were assessed using enzyme-linked immunosorbent assay. Contrast-enhanced computed tomography was used for imaging. Results. During therapy, the patient reported improved well-being, increased productivity and physical activity, and normalized sleep and appetite. Her Karnofsky performance status improved, tumor necrosis factor-alpha levels increased, and tumor markers decreased: carcinoembryonic antigen by 4.2 times and cancer antigen 19-9 by 2.4 times. According to the computed tomography scan with contrast, the patient showed increasing stabilization of the tumor process. The patient has now completed six courses of recombinant tumor necrosis factor-thymosin-α1 therapy in combination with chemotherapy, and treatment is ongoing. Overall survival since diagnosis is 7+ months. Conclusion. The combination of polychemotherapy according to the XELOX regimen and the cytokine genetic therapy drug tumor necrosis factor-thymosin-α1 recombinant is not accompanied by an increase in the toxicity of cytostatics, but has a synergistic antitumor effect.